Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
09/19/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
08/10/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
06/28/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
06/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
05/15/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
04/21/2023 | 587.02% | HC Wainwright & Co. | $20 → $9 | Maintains | Buy |
11/08/2022 | 587.02% | Canaccord Genuity | → $9 | Initiates Coverage On | → Buy |
09/02/2021 | 52.67% | Cantor Fitzgerald | → $2 | Initiates Coverage On | → Overweight |
05/14/2021 | 52.67% | HC Wainwright & Co. | $1.5 → $2 | Maintains | Buy |
05/04/2020 | 14.5% | HC Wainwright & Co. | $2 → $1.5 | Reiterates | → Buy |
09/06/2019 | 52.67% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
03/19/2019 | 14.5% | Wells Fargo | $6 → $1.5 | Maintains | Market Perform |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年09月21日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023/09/19 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023年08月10日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023年6月28日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023年6月21日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023年05月15日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
04/21/2023 | 587.02% | HC Wainwright公司 | $20→$9 | 维护 | 买 |
11/08/2022 | 587.02% | 卡纳科特·格纳奇 | →$9 | 开始承保 | →购买 |
09/02/2021 | 52.67% | 康托·菲茨杰拉德 | →$2 | 开始承保 | →超重 |
2021/05/14 | 52.67% | HC Wainwright公司 | $1.5→$2 | 维护 | 买 |
05/04/2020 | 14.5% | HC Wainwright公司 | $2→$1.5 | 重申 | →购买 |
2019年06月09日 | 52.67% | HC Wainwright公司 | →$2 | 开始承保 | →购买 |
2019/03/19 | 14.5% | 富国银行 | $6→$1.5 | 维护 | 市场表现 |
What is the target price for Regulus Therapeutics (RGLS)?
Regulus Treeutics(RGLS)的目标价格是多少?
The latest price target for Regulus Therapeutics (NASDAQ: RGLS) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 587.02% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年9月21日报道了Regulus治疗公司(纳斯达克:RGLS)的最新目标价。这家分析公司将目标价定为9美元,预计RGLS将在12个月内升至(可能上涨587.02%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Regulus Therapeutics (RGLS)?
Regulus Treeutics(RGLS)的最新分析师评级是多少?
The latest analyst rating for Regulus Therapeutics (NASDAQ: RGLS) was provided by HC Wainwright & Co., and Regulus Therapeutics reiterated their buy rating.
对Regulus治疗公司(纳斯达克代码:RGLS)的最新分析师评级由HC Wainwright&Co.提供,Regulus治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?
Regulus治疗公司(RGLS)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析师在进行了广泛的研究后得出股票评级,其中包括查阅公共财务报表,与Regulus Treeutics的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。Regulus治疗公司的最后一次评级是在2023年9月21日提交的,所以你应该预计下一次评级将在2024年9月21日左右的某个时候提供。
Is the Analyst Rating Regulus Therapeutics (RGLS) correct?
分析师评级Regulus Treeutics(RGLS)正确吗?
While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.31, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的Regulus治疗公司(RGLS)的评级被重申,目标价在0.00美元到9.00美元之间。Regulus治疗公司(RGLS)目前的交易价格为1.31美元,在分析师的预测范围内。